Ethyl 2-(4-Hydroxyphenyl)-4-methylthiazole-5-carboxylate

CAS: 161797-99-5

Ref. TR-E918910

Produktinformation

• Name: Ethyl 2-(4-Hydroxyphenyl)-4-methylthiazole-5-carboxylate
• Synonyme: 2-(4-Hydroxyphenyl)-4-methylthiazole-5-carboxylic Acid Ethyl Ester, Ethyl 2-(4-Hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate, 2-(4-Hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, 2-(4-Hydroxyphenyl)-4-methylthiazole-5-carboxytic acid ethyl ester, 5-Thiazolecarboxylic acid, 2-(4-hydroxyphenyl)-4-methyl-, ethyl ester, Ethyl 2-(4-HydroxyPhenyl)-4-Methyl Thiazole-5-Carboxylate, Ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, Ethyl-2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl2-(4-hydroxy phenyl)-4-methylthiazole-5-carboxylate, Febuxostat N-2

Beschreibung

Applications Ethyl 2-(4-Hydroxyphenyl)-4-methylthiazole-5-carboxylate is used in the synthesis of the major metabolites of Febuxostat (F229000), a xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout.
References Li, X., et. al.: Lett. Org. Chem., 12, 217 (2015); Vallu, V., et. al.: Anal. Chem. Indian J., 14, 339 (2014); Osada, Y., et al.: Eur. J. Pharmacol., 241, 183 (1993); Okamoto, K., et al.: J. Biol. Chem., 278, 1848 (2003); Mayer, M.D., et al.: Am. J. Therap., 12, 22 (2005); Tomlinson, B., et al.: Curr. Opin. Invest. Drugs, 6, 1168 (2005)

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 263.31
• Formel: C₁₃H₁₃NO₃S
• Farbe/Form: Neat
• InChl: InChI=1S/C13H13NO3S/c1-3-17-13(16)11-8(2)14-12(18-11)9-4-6-10(15)7-5-9/h4-7,15H,3H2,1-2H3